

# Preventing surgical-site infections in primary total hip and total knee prosthesis.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Pending
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON20376

### Source

NTR

### Brief title

Mupirocine Prophylaxis Infection trial (MuPi trial)

### Health condition

surgical site infections  
primary total knee replacement  
primary total hip replacement

diepe wondinfecties  
totale heup prothese  
totale knie prothese  
eradicatie kuur

## Sponsors and support

**Primary sponsor:** Isala Clinics Zwolle the Netherlands

**Source(s) of monetary or material Support:** Achmea health care

## Intervention

## Outcome measures

### Primary outcome

Reduction in surgical site infection

### Secondary outcome

Decolonization of *S. aureus*, swabs during surgery and before start intervention

## Study description

### Study objective

Mupirocin nasal ointment and chlorhexidine soap, reduces the risk of hospital-associated *S. aureus* infection in primary hip and knee replacement

### Study design

Inclusion will take three years in total, after inclusion follow-up will be one year. After four years all patients have enrolled the study with a minimal follow-up of one year

### Intervention

The intervention and control group starts five days before surgery with nasal ointment and bathing

## Contacts

### Public

R. Rolink  
Isala Klinieken  
Thorbeckegracht 54  
Zwolle 8011 VP  
The Netherlands

### Scientific

R. Rolink  
Isala Klinieken  
Thorbeckegracht 54  
Zwolle 8011 VP  
The Netherlands

## Eligibility criteria

### Inclusion criteria

- All patients have to be mentally competent
- Informed consent
- Age above 18
- Primary total hip replacement or primary total knee replacement

### Exclusion criteria

- Not mentally competent
- Allergy for substances
- No previous hip or knee surgery before (arthroscopy is allowed)

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

### Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-01-2015

Enrollment: 12000  
Type: Anticipated

## Ethics review

Positive opinion  
Date: 25-08-2014  
Application type: First submission

## Study registrations

### Followed up by the following (possibly more current) registration

ID: 41616  
Bron: ToetsingOnline  
Titel:

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
NTR-new	NL4605
NTR-old	NTR4756
CCMO	NL32100.075.11
OMON	NL-OMON41616

## Study results